HealthCare Royalty Partners Appoints Pfizer Veteran to Strategic Advisory Board

STAMFORD, CT – December 4, 2013 – HealthCare Royalty Partners (“HC Royalty”), a global healthcare investment firm, today announced the appointment of Natale Ricciardi, former President, Pfizer Global Manufacturing and Senior Vice President, Pfizer Inc., to the firm’s Strategic Advisory Board.

“Nat led a distinguished career at Pfizer for nearly four decades and helped create the premier quality-focused manufacturing operation in the pharmaceutical industry. We are honored to have him join our growing list of strategic advisors. Nat’s insights and expertise in pharmaceutical operations will be invaluable,” said Todd Davis, Founding Managing Director at HC Royalty.

Mr. Ricciardi spent his entire 39-year biopharmaceutical career at Pfizer Inc. and retired in 2011 as a member of the Pfizer Executive Leadership Team. In addition to his corporate leadership role, he was directly responsible for all of Pfizer’s internal and external supply organization, a global enterprise that grew to more than 100 manufacturing facilities supplying small and large molecule pharmaceuticals, vaccines, consumer, nutrition and animal health products. A native of Italy, Mr. Ricciardi received a Bachelor of Science degree in Chemical Engineering from The City College of New York and a Master of Business Administration in Finance and International Business from Fordham University.  He currently serves on the Board of Directors of Dynavax Technologies.

“I have been thoroughly impressed with the team at HC Royalty. They are smart investors with a broad and robust platform. I look forward to supporting them in their future growth,” commented Nat Ricciardi.

About HealthCare Royalty Partners
HealthCare Royalty Partners is a global healthcare investment firm that provides financing solutions to healthcare companies and royalty owners with interests in approved pharmaceutical and medical device products. The firm’s senior investment team has participated in nearly 50 royalty financings valued at over $2 billion over the past decade. For more information, visit

Synthetic Royalty® is a registered trademark of HealthCare Royalty Management, LLC.

# # #